Shrividya Iyer

Pfizer (United States) — United States

Medicine · Health Sciences

26h-index9.9kcitations114works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(36), Lung Cancer Treatments and Mutations(23), HER2/EGFR in Cancer Research(18), Cancer Treatment and Pharmacology(18), Lung Cancer Diagnosis and Treatment(13)

Publications113 total

Abstract PS5-04-01: Survival Outcomes in Metastatic Breast Cancer: An analysis of the US population-based SEER database
Clinical Cancer Research·2026
Investigating the Role of Lifestyle Modifications and Yoga Intervention in the Management of Type 2 Diabetes: A Comprehensive Review
Journal of Information Systems Engineering & Management·2025Open Access
Martha Chase at the University of Rochester: The Woman in STEM Who Was Forgotten
Journal of Undergraduate Research·2024Open Access
Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States
World Journal of Gastrointestinal Oncology·2023· 5 citedOpen Access
Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer·2023· 11 citedOpen Access
<scp>Real‐world</scp> effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in <scp>US</scp> clinical practice
Cancer Reports·2022· 5 citedOpen Access
The Lost Loop: A Case of a Forgotten Lippes Loop in a Menopausal Woman Leading to Pyometra and Spontaneous Uterine Perforation
International Journal of Science and Research (IJSR)·2022Open Access
Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis
Clinical Gastroenterology and Hepatology·2021· 5 cited
Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices.
Journal of Clinical Oncology·2021
Real-World Effectiveness of Lenvatinib Monotherapy Among Unresectable Hepatocellular Carcinoma Patients in the USA
Future Oncology·2021· 24 citedOpen Access
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.
Journal of Clinical Oncology·2021· 1 cited
316P Real-world treatment patterns and clinical effectiveness outcomes of eribulin in metastatic breast cancer patients in community oncology centers in the United States
Annals of Oncology·2020
Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]
The Breast·2019Open Access
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
Journal of Global Oncology·2019· 71 citedOpen Access
Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study
Journal of Global Oncology·2019· 53 citedOpen Access
Abstract P6-18-33: GI toxicities in metastatic breast cancer: A comprehensive literature review
Cancer Research·2019
Abstract P6-18-21: Real world treatment patterns and outcomes of patients receiving palbociclib plus fulvestrant in the United States: Sub-groups analysis based on age, performance status and sites of metastases
Cancer Research·2019· 2 cited
Abstract P6-18-36: Real world treatment patterns and outcomes of patients receiving palbociclib plus aromatase inhibitor in the United States: Sub-groups analysis based on age, performance status and sites of metastases from the IRIS study
Cancer Research·2019· 1 cited
Abstract P6-18-29: Real-world treatment patterns and clinical outcomes with palbociclib combination therapy received in US community oncology practices
Cancer Research·2019· 1 cited
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Breast Cancer Research and Treatment·2019· 415 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Debanjali Mitra(9), Keith D. Wilner(8), Arlene Reisman(8), Benjamin Solomon(7), Fiona Blackhall(7), Cynthia Huang Bartlett(7), Alice T. Shaw(6), Nadia Harbeck(6), A. Mori(6), Tony Mok(5), Richard S. Finn(5), Johannes Ettl(5), Dongrui R. Lu(5), Yi‐Long Wu(4), Hope S. Rugo(4), Véronique Dièras(4), Karen A. Gelmon(4), Gavin Taylor‐Stokes(4), Helen Bhattacharyya(4), Ji‐Youn Han(4)